Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251898 | 0.90 | HTR6 (0.51) | HTR6 | |
| SCHEMBL5253364 | 0.85 | HTR6 (0.66) | HTR6CYP3A4CYP2A6HTR2CHTR7 | |
| SCHEMBL5255297 | 0.80 | HTR6 (0.62) | HTR6CYP3A4CYP2A6HTR2CHTR7 | |
| SCHEMBL5255361 | 0.77 | HTR6 (1.00) | HTR6 | |
| SCHEMBL5251020 | 0.75 | HTR6 (1.00) | HTR6 | |
| SCHEMBL5255585 | 0.73 | HTR6 (1.00) | HTR6CYP3A4HTR1A | |
| SCHEMBL5254765 | 0.73 | HTR6 (0.49) | HTR6 | |
| SCHEMBL5738683 | 0.72 | HTR6 (0.67) | HTR6CYP3A4CYP2A6HTR2CHTR7 | |
| SCHEMBL5255669 | 0.72 | HTR6 (1.00) | HTR6HTR1A | |
| SCHEMBL5309054 | 0.72 | HTR6 (0.77) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355904-B1 | HETEROCYCLINDAZOLE AND AZAINDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-08-01 | — | — | EP | claimed |
| EP-1803720-A1 | Heterocyclindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | Wyeth a Corporation of the State of Delaware (US) | 2007-07-04 | — | — | EP | claimed |
| US-6903112-B2 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-07 | — | — | US | claimed |
| US-20040092526-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-13 | — | — | US | claimed |
| US-20020198213-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | AMERICAN HOME PRODUCTS CORPORATION | 2002-12-26 | — | — | US | claimed |
| EP-1355904-B1 | HETEROCYCLINDAZOLE AND AZAINDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1803720-A1 | Heterocyclindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | Wyeth a Corporation of the State of Delaware (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20050124603-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-09 | — | — | US | disclosed |
| US-6903112-B2 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| US-6767912-B2 | SUCH AS 1-(PHENYLSULFONYL)-3-(PIPERIDIN-4-YL)-1H-INDAZOLE; FOR MOOD, MOTOR, OR COGNITIVE DISORDERS INCLUDING SCHIZOPHRENIA, ANXIETY, AND DEPRESSION | WYETH | 2004-07-27 | — | — | US | disclosed |
| US-20040092526-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-13 | — | — | US | disclosed |
| US-20020198213-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | AMERICAN HOME PRODUCTS CORPORATION | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092526-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | HTR6 1/4885CYP3A4 317/4885CYP2A6 132/4885 |
| US-20050124603-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR3B | HTR6 1/4885CYP3A4 288/4885CYP2A6 114/4885 |
| US-20020198213-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | HTR6 1/4885CYP3A4 317/4885CYP2A6 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.